We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Spray-On Barrier Curbs Laparoscopic Surgical Adhesions

By HospiMedica International staff writers
Posted on 09 Aug 2011
A spray-on combination of hyaluronic acid (HA) and cellulose might help reduce postoperative adhesions, according to a new study.

Researchers at Thomas Jefferson University (Philadelphia, PA, USA), Wayne State University School of Medicine (Wayne State, Detroit, MI, USA), and other institutions conducted a multicenter, randomized, reviewer-blinded trial involving 41 women undergoing laparoscopic myomectomy. More...
The participants were randomized to treatment with (21 patients) or without (20 patients) use of Sepraspray Adhesion Barrier, a modified HA and carboxymethylcellulose powder. The main outcome measures were postoperative adhesions development, as assessed at early second-look laparoscopy.

The results showed that median operative time was increased by only 3 minutes in the treatment group. Both groups had increased adhesions associated with the creation of one or more uterine incisions at the initial laparoscopy, but for anterior and anterior uterine surfaces the increases tended to be smaller in the spray group. This was also true of the uterus as a whole; the increase in the score was more than twice as large in the control group as in the spray group. The spray group was also more likely to have either side of the uterus free of dense adhesions (95% versus 70%). There was no overall between-group difference in the number of patients with adverse events, nor were any adverse events directly linked to use of the spray. The study was published in the August 2011 issue of Fertility and Sterility.

“There is a tremendous medical need for development of adjuvants to reduce postoperative adhesions, over and above the benefits achievable by the use of meticulous surgical technique,” said study coauthor Michael Diamond, MD, of Wayne State, who is also a consultant for Genzyme Corporation (Cambridge, MA, USA), the manufacturer of the Sepraspray Adhesion Barrier.

Postoperative intra-abdominal and pelvic adhesions involve the nonanatomic connection of fibrous tissue between normal peritoneal surfaces. Adhesions are a leading cause of infertility, chronic pelvic pain, and intestinal obstruction. Although not commonly recognized, the incidence ranges between 55% and 95% after abdominal or pelvic surgery. It is generally considered that some people are more prone to develop postoperative adhesions than are others; unfortunately, there is no available marker to predict the occurrence, extent, and severity of adhesions preoperatively. Additionally, there are no available serum markers or imaging studies that are able to predict the incidence, severity, or extent of adhesions.

Related Links:

Thomas Jefferson University
Wayne State University School of Medicine
Genzyme Corporation



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.